Infectious Diseases Diagnostics Global Market-Forecast to 2027

Publishing Date : August, 2020
Report Code : HCMD0172
Price:
Single license $4,950
Site license $6,750
Global license $9,000


Note: The report would be dispatched after confirmation of payment

Infectious Disease Diagnostics (IDD) comprises of various diagnostics technologies and platforms used by healthcare professionals to detect and diagnose infectious diseases causing pathogens in human samples, including blood, serum, throat swabs, urine, and stool. It enables healthcare professionals for early diagnosis of the diseases and serves the patient population with better care management in less time and cost. With growing technological advancements, the IDD platforms are increasingly becoming more useful to serve the patients with a more convenient, faster, and highly accurate diagnosis. It helps the end-users to provide a cost-effective diagnostics process to the patient population.

An estimated by IQ4I Research, the Infectious Disease Diagnostics global market is expected to reach $26,028.0 million by 2027 growing at a low single digit CAGR from 2020 to 2027. Some of the factors such as the increasing prevalence of infectious diseases, the requirement of early detection for infectious disease, increasing point of care diagnostics and rapid diagnostics, favorable reimbursements, technological advancements and rising investments in diagnostics.

The Infectious Disease Diagnostics market based on product is segmented into consumables, instruments, and software & services. The consumables segment accounted for the largest revenue in 2020 and is expected to grow at a strong low single digit CAGR from 2020 to 2027.

The Infectious Disease Diagnostics market based on technology is segmented into molecular diagnostics, immunodiagnostics, and others (mass spectroscopy, culture media). Among these, the immunodiagnostics segment accounted for the largest revenue in 2020 and is expected to grow at a low single digit CAGR from 2020 to 2027. The molecular diagnostics segment is the fastest-growing segment growing at a low single digit CAGR from 2020 to 2027 due to the increasing prevalence of infectious diseases and technological advancements.

IDD Molecular diagnostics global market based on product type, it is segmented into PCR, INAAT, Microarray, NGS, ISH, and others. Among these, the PCR segment accounted for the largest revenue in 2020 and is expected to grow at a low single digit CAGR from 2020 to 2027 due to the high prevalence of infectious disease, technological advancements and rise in the number of diagnostic centers and hospitals. The NGS segment is the fastest-growing segment growing at a low single digit CAGR from 2020 to 2027 due to the advancements and declining costs of NGS platforms and improving regulatory and reimbursement scenario for NGS based diagnostic tests.

IDD Immunodiagnostics global market based on product type, it is segmented into CHLIA, Lateral flow Immunochromatography assay (LFIA), Enzyme Immunoassay (EIA), Fluorescent Immunoassay (FIA) and others. Among these, the LFIA segment accounted for the largest revenue in 2020 and is expected to grow at a low single digit CAGR from 2020 to 2027 due to the high prevalence of infectious diseases, increase in demand for home-based lateral flow assay test kits and surge in demand for point-of-care testing. The EIA segment is the fastest-growing segment growing at a low single digit CAGR from 2020 to 2027. The fastest growth rate of this segment is due to the increasing incidence of infectious diseases and increasing demand for cost-effective EIA test kits for diagnosis for various infectious diseases.

Infectious Disease Diagnostics global market based on application is segmented into a bacterial infection, viral infection, fungal infection, and other infections. Among these applications, viral infection diagnostics segment holds the highest revenue in 2020 and is expected to grow at a low single digit CAGR from 2020 to 2027 due to rising prevalence of HIV, hepatitis, influenza, rubella, increasing demand for more rapid diagnostic test kits for influenza and rising adoption of diagnostic kits for viral infections by physicians.

Bacterial infection diagnostics global market based on application type, it is segmented into Treponema pallidum, Gardnerella, Staphylococcus aureus, Clostridium difficile, Streptococcus (A&B), Methicillin-resistant Staphylococcus aureus (MRSA), Chlamydia trachomatis (CT) & Neisseria gonorrhea (NG) and tuberculosis (TB) and others. Among these, Staphylococcus Aureus holds the largest in 2020 and is expected to grow at a low single digit CAGR from 2020 to 2027. The Tuberculosis segment is the fastest-growing growing at a strong mid single digit CAGR from 2020 to 2027.

Viral infection diagnostics global market based on application type, it is segmented into HIV-1, influenza, dengue, Hepatitis B, Hepatitis C, Human papillomavirus (HPV), herpes simplex virus (HSC), zika virus, and others. Among these, HIV-1 holds the largest revenue in 2020 and is expected to grow at a mid teen CAGR from 2020 to 2027.

Fungal infection diagnostics global market based on application type, it is segmented into Candida, Aspergillus, and others. Among these, Candida holds the largest revenue in 2020 and is expected to grow at a strong low single digit CAGR from 2020 to 2027.

Other infections diagnostics global market based on application type, it is segmented into Malaria, Trichomonas vaginalis, and others. Among these, Trichomonas Vaginalis holds the largest revenue in 2020 and is expected to grow at a low single digit CAGR from 2020 to 2027. The Malaria segment is the fastest-growing segment growing with a strong low single digit CAGR from 2020 to 2027.

Infectious Disease Diagnostics global market based on end-users is segmented into hospitals, ambulatory surgical centers (ASC) & clinics, centralized laboratory & clinical trials, academics & research institutes, and others (home care, self-test and blood banks). Among end-users, the hospitals, ASCs & clinics segment holds the highest revenue in 2020 and is expected to grow at a low single digit CAGR from 2020 to 2027. Centralized Laboratories segment is the fastest-growing segment growing with a strong low single digit CAGR from 2020 to 2027.

Infectious Disease Diagnostics global market based on the mode of the test is segmented into centralized laboratories and Point-of-care (POC). Among these, the centralized laboratories segment holds the highest revenue in 2020 and is expected to grow at a mid single digit CAGR from 2020 to 2027. The POC segment holds the second largest revenue in 2020 due to the rising prevalence of infectious diseases, technological advancements in POC testing products and growing patient awareness of POC testing are some of the major factors driving the POC market.

Infectious Disease Diagnostics market by region is segmented as North America (U.S. and Rest of North America), Europe (Germany, France, Italy and Rest of Europe), Asia-Pacific (China, Japan, India and Rest of APAC) and Rest of the world (Brazil, Rest of LATAM and the Middle East & Africa). North America holds the highest revenue in 2020 and is expected to grow at a low single digit CAGR from 2020 to 2027 due to the adoption of the technological advancements, presence of a highly developed healthcare system, increasing incidence of infectious diseases, the presence of a large number of leading national clinical laboratories, increasing reimbursement scheme by the government, product launches, skilled personnel, investments, and funds. The Asia-Pacific region is the fastest-growing region growing with a strong mid single digit CAGR from 2020 to 2027 due to the increasing healthcare awareness, increasing prevalence of influenza, malaria and TB, government funding in developing countries.

The report provides an in-depth market analysis of the above-mentioned segments across the following regions:

  • North America
  • U.S.
  • Rest of North America
  • Europe
  • Germany
  • France
  • Italy
  • Rest of Europe
  • Asia-Pacific 
  • Japan
  • China
  • Indian
  • Rest of APAC
  • Rest of the World (RoW)
  • Brazil
  • Rest of LATAM
  •  Middle East and Africa
  • 1     EXECUTIVE SUMMARY
  • 2     INTRODUCTION
    • 2.1     KEY TAKEAWAYS
    • 2.2     SCOPE OF THE REPORT
    • 2.3     REPORT DESCRIPTION
    • 2.4     MARKETS COVERED
    • 2.5     STAKEHOLDERS
    • 2.6     RESEARCH METHODOLOGY
      • 2.6.1     MARKET SIZE ESTIMATION
      • 2.6.2     MARKET BREAKDOWN AND DATA TRIANGULATION
      • 2.6.3     SECONDARY SOURCES
      • 2.6.4     PRIMARY SOURCES
      • 2.6.5     KEY DATA POINTS FROM SECONDARY SOURCES
      • 2.6.6     KEY DATA POINTS FROM PRIMARY SOURCES
      • 2.6.7     ASSUMPTIONS
  • 3     MARKET ANALYSIS
    • 3.1     INTRODUCTION
    • 3.2     MARKET SEGMENTATION
    • 3.3     FACTORS INFLUENCING MARKET
      • 3.3.1     DRIVERS AND OPPORTUNITIES
        • 3.3.1.1     INCREASING PREVALENCE OF INFECTIOUS DISEASES
        • 3.3.1.2     REQUIREMENT OF EARLY DETECTION OF INFECTIOUS DISEASE
        • 3.3.1.3     INCREASING POINT OF CARE DIAGNOSTICS AND RAPID DIAGNOSTICS
        • 3.3.1.4     FAVORABLE REIMBURSEMENTS
        • 3.3.1.5     TECHNOLOGICAL ADVANCEMENTS
        • 3.3.1.6     RISING INVESTMENTS IN INFECTIOUS DISEASE DIAGNOSTICS
      • 3.3.2     RESTRAINTS AND THREATS
        • 3.3.2.1     LACK OF SKILLED PROFESSIONALS
        • 3.3.2.2     THE HIGH COST OF INFECTIOUS DISEASE DIAGNOSTIC TECHNOLOGIES AND TESTS
        • 3.3.2.3     LACK OF REPRODUCIBILITY AND REPEATABILITY
        • 3.3.2.4     STRINGENT REGULATORY GUIDELINES
    • 3.4     REGULATORY AFFAIRS
      • 3.4.1     INTERNATIONAL ORGANIZATION FOR STANDARDIZATION
        • 3.4.1.1     ISO 9001: 2015 QUALITY MANAGEMENT SYSTEM
        • 3.4.1.2     ISO 16256: 2012 CLINICAL LABORATORY TESTING AND IN VITRO DIAGNOSTIC TEST SYSTEMS
        • 3.4.1.3     ISO /TS 16782: 2016 CLINICAL LABORATORY TESTING
        • 3.4.1.4     ISO/TS 17518: 2015 MEDICAL LABORATORIES- REAGENTS FOR STAINING BIOLOGICAL MATERIAL
        • 3.4.1.5     ISO20776-1:2019 SUSCEPTIBILITY TESTING OF INFECTIOUS AGENTS AND EVALUATION OF THE PERFORMANCE OF ANTIMICROBIAL SUSCEPTIBILITY TEST DEVICE
      • 3.4.2     U.S.
      • 3.4.3     EUROPE
      • 3.4.4     CHINA
      • 3.4.5     INDIA
      • 3.4.6     JAPAN
      • 3.4.7     SOUTH KOREA
    • 3.5     TECHNOLOGICAL ADVANCEMENTS
      • 3.5.1     NANOTRAP VIRUS CAPTURE KIT
      • 3.5.2     RNASCOPE CHROMOGENIC ASSAYS
      • 3.5.3     NEXT-GENERATION SEQUENCING (NGS)
      • 3.5.4     LOOP-MEDIATED ISOTHERMAL AMPLIFICATION (LAMP)
      • 3.5.5     PORTABLE DNA SEQUENCER
      • 3.5.6     NANOPIN DIAGNOSTIC PLATFORM
      • 3.5.7     LUMINEX XMAP TECHNOLOGY
    • 3.6     PORTER’S FIVE FORCE ANALYSIS
      • 3.6.1     THREAT OF NEW ENTRANTS
      • 3.6.2     THREAT OF SUBSTITUTES
      • 3.6.3     BARGAINING POWER OF SUPPLIERS
      • 3.6.4     BARGAINING POWER OF BUYERS
      • 3.6.5     COMPETITIVE RIVALRY
    • 3.7     SUPPLY CHAIN ANALYSIS
    • 3.8     REIMBURSEMENT SCENARIO
    • 3.9     FUNDING SCENARIO
    • 3.10     MARKET SHARE ANALYSIS BY MAJOR PLAYERS
      • 3.10.1     INFECTIOUS DISEASE DIAGNOSTICS GLOBAL MARKET SHARE ANALYSIS
      • 3.10.2     MOLECULAR DIAGNOSTICS GLOBAL MARKET SHARE ANALYSIS
      • 3.10.3     IMMUNO DIAGNOSTICS GLOBAL MARKET SHARE ANALYSIS
      • 3.10.4     POINT OF CARE (POC) DIAGNOSTICS GLOBAL MARKET SHARE ANALYSIS
    • 3.11     CORONAVIRUS (COVID-19)
    • 3.12     FDA-EUA APPROVED DIAGNOSTICS TESTS
    • 3.13     INFECTIOUS DISEASE DIAGNOSTICS GLOBAL MARKET, BY MODE OF TRANSMISSION
    • 3.14     INFECTIOUS DISEASE DIAGNOSTICS COMPANY COMPARISON TABLE BY APPLICATION, SOURCE, TECHNOLOGY
  • 4     INFECTIOUS DISEASE DIAGNOSTICS GLOBAL MARKET, BY PRODUCT
    • 4.1     INTRODUCTION
    • 4.2     CONSUMABLES
    • 4.3     INSTRUMENTS
    • 4.4     SOFTWARE & SERVICES
  • 5     INFECTIOUS DISEASE DIAGNOSTICS GLOBAL MARKET, BY TECHNOLOGY
    • 5.1     INTRODUCTION
    • 5.2     IDD MOLECULAR DIAGNOSTICS
      • 5.2.1     POLYMERASE CHAIN REACTION (PCR)
      • 5.2.2     ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY (INAAT)
      • 5.2.3     MICROARRAY
      • 5.2.4     NEXT-GENERATION SEQUENCING (NGS)
      • 5.2.5     IN-SITU HYBRIDIZATION (ISH)
      • 5.2.6     OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES
    • 5.3     IDD IMMUNO DIAGNOSTICS
      • 5.3.1     CHEMILUMINESCENCE IMMUNOASSAY (CHLIA)
      • 5.3.2     LATERAL FLOW IMMUNOCHROMATOGRAPHY ASSAY (LFIA)
      • 5.3.3     ENZYME IMMUNOASSAY (EIA)
      • 5.3.4     FLUORESCENT IMMUNOASSAY (FIA)
      • 5.3.5     OTHER IMMUNO DIAGNOSTIC TECHNOLOGIES
    • 5.4     IDD OTHER DIAGNOSTICS
  • 6     INFECTIOUS DISEASE DIAGNOSTICS GLOBAL MARKET, BY APPLICATION
    • 6.1     INTRODUCTION
    • 6.2     BACTERIAL INFECTION
      • 6.2.1     TREPONEMA PALLIDUM
      • 6.2.2     GARDNERELLA VAGINALIS
      • 6.2.3     STAPHYLOCOCCUS AUREUS
      • 6.2.4     CLOSTRIDIUM DIFFICILE
      • 6.2.5     STREPTOCOCCUS (A & B)
      • 6.2.6     METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS (MRSA)
      • 6.2.7     CHLAMYDIA TRACHOMATIS (CT) AND NEISSERIA GONORRHOEAE (NG)
      • 6.2.8     TUBERCULOSIS (TB)
      • 6.2.9     OTHER BACTERIAL INFECTION
    • 6.3     VIRAL INFECTION
      • 6.3.1     HIV-1
      • 6.3.2     INFLUENZA
      • 6.3.3     DENGUE
      • 6.3.4     HEPATITIS B
      • 6.3.5     HEPATITIS C
      • 6.3.6     HUMAN PAPILLOMAVIRUS (HPV)
      • 6.3.7     HERPES SIMPLEX VIRUS (HSV)
      • 6.3.8     ZIKA VIRUS
      • 6.3.9     OTHER VIRAL INFECTION
    • 6.4     FUNGAL INFECTION
      • 6.4.1     CANDIDA
      • 6.4.2     ASPERGILLUS
      • 6.4.3     OTHER FUNGAL INFECTION
    • 6.5     OTHER INFECTION
      • 6.5.1     MALARIA
      • 6.5.2     TRICHOMONAS VAGINALIS
      • 6.5.3     OTHER INFECTIONS
  • 7     INFECTIOUS DISEASE DIAGNOSTICS GLOBAL MARKET, BY END-USER
    • 7.1     INTRODUCTION
    • 7.2     HOSPITAL, AMBULATORY SURGICAL CENTERS (ASCS) & CLINICS
    • 7.3     CENTRALIZED LABORATORIES AND CLINICAL TRIALS
    • 7.4     ACADEMICS AND RESEARCH INSTITUTES
    • 7.5     OTHER END-USERS
  • 8     INFECTIOUS DISEASE DIAGNOSTICS GLOBAL MARKET, BY MODE OF TESTING
    • 8.1     INTRODUCTION
    • 8.2     CENTRALIZED LABORATORIES
    • 8.3     POINT OF CARE
  • 9     REGIONAL ANALYSIS
    • 9.1     INTRODUCTION
    • 9.2     NORTH AMERICA
      • 9.2.1     U.S.
      • 9.2.2     REST OF NORTH AMERICA
    • 9.3     EUROPE
      • 9.3.1     GERMANY
      • 9.3.2     FRANCE
      • 9.3.3     ITALY
      • 9.3.4     REST OF EUROPE
    • 9.4     APAC
      • 9.4.1     JAPAN
      • 9.4.2     CHINA
      • 9.4.3     INDIA
      • 9.4.4     REST OF APAC
    • 9.5     ROW
      • 9.5.1     BRAZIL
      • 9.5.2     REST OF LATAM
      • 9.5.3     MIDDLE EAST & AFRICA
  • 10     COMPETITIVE LANDSCAPE
    • 10.1     INTRODUCTION
    • 10.2     PRODUCT APPROVAL
    • 10.3     NEW PRODUCT LAUNCH
    • 10.4     OTHERS
  • 11     MAJOR COMPANIES
    • 11.1     ABBOTT LABORATORIES
      • 11.1.1     OVERVIEW
      • 11.1.2     FINANCIALS
      • 11.1.3     PRODUCT PORTFOLIO
      • 11.1.4     KEY DEVELOPMENTS
      • 11.1.5     BUSINESS STRATEGY
      • 11.1.6     SWOT ANALYSIS
    • 11.2     BECTON, DICKINSON AND COMPANY
      • 11.2.1     OVERVIEW
      • 11.2.2     FINANCIALS
      • 11.2.3     PRODUCT PORTFOLIO
      • 11.2.4     KEY DEVELOPMENTS
      • 11.2.5     BUSINESS STRATEGY
      • 11.2.6     SWOT ANALYSIS
    • 11.3     BIOMERIEUX SA
      • 11.3.1     OVERVIEW
      • 11.3.2     FINANCIALS
      • 11.3.3     PRODUCT PORTFOLIO
      • 11.3.4     KEY DEVELOPMENTS
      • 11.3.5     BUSINESS STRATEGY
      • 11.3.6     SWOT ANALYSIS
    • 11.4     BIO-RAD LABORATORIES, INC.
      • 11.4.1     OVERVIEW
      • 11.4.2     FINANCIALS
      • 11.4.3     PRODUCT PORTFOLIO
      • 11.4.4     KEY DEVELOPMENTS
      • 11.4.5     BUSINESS STRATEGY
      • 11.4.6     SWOT ANALYSIS
    • 11.5     DANAHER CORPORATION
      • 11.5.1     OVERVIEW
      • 11.5.2     FINANCIALS
      • 11.5.3     PRODUCT PORTFOLIO
      • 11.5.4     KEY DEVELOPMENTS
      • 11.5.5     BUSINESS STRATEGY
      • 11.5.6     SWOT ANALYSIS
    • 11.6     F. HOFFMANN-LA ROCHE LTD
      • 11.6.1     OVERVIEW
      • 11.6.2     FINANCIALS
      • 11.6.3     PRODUCT PORTFOLIO
      • 11.6.4     KEY DEVELOPMENTS
      • 11.6.5     BUSINESS STRATEGY
      • 11.6.6     SWOT ANALYSIS
    • 11.7     HOLOGIC, INC.
      • 11.7.1     COVERVIEW
      • 11.7.2     FINANCIALS
      • 11.7.3     PRODUCT PORTFOLIO
      • 11.7.4     KEY DEVELOPMENTS
      • 11.7.5     BUSINESS STRATEGY
      • 11.7.6     SWOT ANALYSIS
    • 11.8     QIAGEN N.V.
      • 11.8.1     OVERVIEW
      • 11.8.2     FINANCIALS
      • 11.8.3     PRODUCT PORTFOLIO
      • 11.8.4     KEY DEVELOPMENTS
      • 11.8.5     BUSINESS STRATEGY
      • 11.8.6     SWOT ANALYSIS
    • 11.9     SIEMENS HEALTHINEERS GMBH
      • 11.9.1     OVERVIEW
      • 11.9.2     FINANCIALS
      • 11.9.3     PRODUCT PORTFOLIO
      • 11.9.4     KEY DEVELOPMENTS
      • 11.9.5     BUSINESS STRATEGY
      • 11.9.6     SWOT ANALYSIS
    • 11.10     THERMO FISHER SCIENTIFIC INC.
      • 11.10.1     OVERVIEW
      • 11.10.2     FINANCIALS
      • 11.10.3     PRODUCT PORTFOLIO
      • 11.10.4     KEY DEVELOPMENTS
      • 11.10.5     BUSINESS STRATEGY
      • 11.10.6     SWOT ANALYSIS

      LIST OF TABLES

      • TABLE 1     INFECTIOUS DISEASE DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 2     NUMBER OF CORONAVIRUS DIAGNOSTICS TEST KIT GLOBAL MARKET, BY REGION, (2020-2027) (NO’S)
      • TABLE 3     CORONAVIRUS DIAGNOSTICS TEST KITS GLOBAL MARKET REVENUE, BY REGION, (2020-2027) ($MN)
      • TABLE 4     INFECTIOUS DISEASE DIAGNOSTICS GLOBAL MARKET REVENUE, BY PRODUCT, (2019-2027) ($MN)
      • TABLE 5     CONSUMABLES GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 6     INSTRUMENTS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 7     SOFTWARE & SERVICES GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 8     INFECTIOUS DISEASE DIAGNOSTICS GLOBAL MARKET REVENUE, BY TECHNOLOGY, (2019-2027) ($MN)
      • TABLE 9     IDD MOLECULAR DIAGNOSTICS GLOBAL MARKET REVENUE, BY TECHNOLOGY TYPE, (2019-2027) ($MN)
      • TABLE 11     IDD MOLECULAR DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 12     PCR GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 13     INAAT GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 14     MICROARRAY GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 15     NGS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 16     ISH GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 17     OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 18     IDD IMMUNO DIAGNOSTICS GLOBAL MARKET REVENUE, BY TECHNOLOGY TYPE, (2019-2027) ($MN)
      • TABLE 20     IDD IMMUNO DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 21     CHLIA GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 22     LFIA GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 23     ENZYME IMMUNOASSAY (EIA) GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 24     FLUORESCENT IMMUNOASSAY (FIA) GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 25     OTHER IMMUNO DIAGNOSTIC TECHNOLOGIES GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 26     IDD OTHER DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 27     INFECTIOUS DISEASE DIAGNOSTICS GLOBAL MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN)
      • TABLE 28     BACTERIAL INFECTION GLOBAL MARKET REVENUE, BY APPLICATION TYPE, (2019-2027) ($MN)
      • TABLE 29     BACTERIAL INFECTION GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 30     TREPONEMA PALLIDUM GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 31     GARDNERELLA VAGINALIS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 32     STAPHYLOCOCCUS AUREUS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 33     CLOSTRIDIUM DIFFICILE GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 34     STREPTOCOCCUS (A & B) GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 35     MRSA GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 36     CT AND NG GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 37     TUBERCULOSIS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 38     OTHER BACTERIAL INFECTION GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 39     VIRAL INFECTION GLOBAL MARKET REVENUE, BY APPLICATION TYPE, (2019-2027) ($MN)
      • TABLE 40     VIRAL INFECTION GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 41     HIV-1 GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 42     INFLUENZA GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 43     DENGUE GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 44     HEPATITIS B GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 45     HEPATITIS C GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 46     HPV GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 47     HSV GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 48     ZIKA VIRUS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 49     OTHER VIRAL INFECTION GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 50     FUNGAL INFECTION GLOBAL MARKET REVENUE, BY APPLICATION TYPE, (2019-2027) ($MN)
      • TABLE 51     FUNGAL INFECTION GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 52     CANDIDA GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 53     ASPERGILLUS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 54     OTHER FUNGAL INFECTION GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 55     OTHER INFECTION GLOBAL MARKET REVENUE, BY APPLICATION TYPE, (2019-2027) ($MN)
      • TABLE 56     OTHER INFECTION GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 57     MALARIA GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 58     TRICHOMONAS VAGINALIS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 59     OTHER INFECTIONS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 60     INFECTIOUS DISEASE DIAGNOSTICS GLOBAL MARKET REVENUE, BY END-USER, (2019-2027) ($MN)
      • TABLE 61     HOSPITAL, ASCS & CLINICS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 62     CENTRALIZED LABORATORY AND CLINICAL TRIALS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 63     ACADEMICS AND RESEARCH INSTITUTES GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 64     OTHER END-USERS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 65     INFECTIOUS DISEASE DIAGNOSTICS GLOBAL MARKET REVENUE, BY MODE OF TESTING, (2019-2027) ($MN)
      • TABLE 66     CENTRALIZED LABORATORIES GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 67     POINT OF CARE GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 68     INFECTIOUS DISEASE DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 69     NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY PRODUCT, (2019-2027) ($MN)
      • TABLE 70     NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY, (2019-2027) ($MN)
      • TABLE 71     NORTH AMERICA IDD MOLECULAR DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY TYPE, (2019-2027) ($MN)
      • TABLE 72     NORTH AMERICA IDD IMMUNO DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY TYPE, (2019-2027) ($MN)
      • TABLE 73     NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN)
      • TABLE 74     NORTH AMERICA BACTERIAL INFECTION MARKET REVENUE, BY APPLICATION TYPE, (2019-2027) ($MN)
      • TABLE 75     NORTH AMERICA VIRAL INFECTION MARKET REVENUE, BY APPLICATION TYPE, (2019-2027) ($MN)
      • TABLE 76     NORTH AMERICA FUNGAL INFECTION MARKET REVENUE, BY APPLICATION TYPE, (2019-2027) ($MN)
      • TABLE 77     NORTH AMERICA OTHER INFECTION MARKET REVENUE, BY APPLICATION TYPE, (2019-2027) ($MN)
      • TABLE 78     NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY END-USER, (2019-2027) ($MN)
      • TABLE 79     NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY MODE OF TESTING, (2019-2027) ($MN)
      • TABLE 80     NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY COUNTRY, (2019-2027) ($MN)
      • TABLE 81     EUROPE INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY PRODUCT, (2019-2027) ($MN)
      • TABLE 82     EUROPE INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY, (2019-2027) ($MN)
      • TABLE 83     EUROPE IDD MOLECULAR DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY TYPE, (2019-2027) ($MN)
      • TABLE 84     EUROPE IDD IMMUNO DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY TYPE, (2019-2027) ($MN)
      • TABLE 85     EUROPE INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN)
      • TABLE 86     EUROPE BACTERIAL INFECTION MARKET REVENUE, BY APPLICATION TYPE, (2019-2027) ($MN)
      • TABLE 87     EUROPE VIRAL INFECTION MARKET REVENUE, BY APPLICATION TYPE, (2019-2027) ($MN)
      • TABLE 88     EUROPE FUNGAL INFECTION MARKET REVENUE, BY APPLICATION TYPE, (2019-2027) ($MN)
      • TABLE 89     EUROPE OTHER INFECTION MARKET REVENUE, BY APPLICATION TYPE, (2019-2027) ($MN)
      • TABLE 90     EUROPE INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY END-USER, (2019-2027) ($MN)
      • TABLE 91     EUROPE INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY MODE OF TESTING, (2019-2027) ($MN)
      • TABLE 92     EUROPE INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY COUNTRY, (2019-2027) ($MN)
      • TABLE 93     APAC INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY PRODUCT, (2019-2027) ($MN)
      • TABLE 94     APAC INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY, (2019-2027) ($MN)
      • TABLE 95     APAC IDD MOLECULAR DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY TYPE, (2019-2027) ($MN)
      • TABLE 96     APAC IDD IMMUNO DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY TYPE, (2019-2027) ($MN)
      • TABLE 97     APAC INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN)
      • TABLE 98     APAC BACTERIAL INFECTION MARKET REVENUE, BY APPLICATION TYPE, (2019-2027) ($MN)
      • TABLE 99     APAC VIRAL INFECTION MARKET REVENUE, BY APPLICATION TYPE, (2019-2027) ($MN)
      • TABLE 100     APAC FUNGAL INFECTION MARKET REVENUE, BY APPLICATION TYPE, (2019-2027) ($MN)
      • TABLE 101     APAC OTHER INFECTION MARKET REVENUE, BY APPLICATION TYPE, (2019-2027) ($MN)
      • TABLE 102     APAC INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY END-USER, (2019-2027) ($MN)
      • TABLE 103     APAC INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY MODE OF TESTING, (2019-2027) ($MN)
      • TABLE 104     APAC INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY COUNTRY, (2019-2027) ($MN)
      • TABLE 105     ROW INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY PRODUCT, (2019-2027) ($MN)
      • TABLE 106     ROW INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY, (2019-2027) ($MN)
      • TABLE 107     ROW IDD MOLECULAR DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY TYPE, (2019-2027) ($MN)
      • TABLE 108     ROW IDD IMMUNO DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY TYPE, (2019-2027) ($MN)
      • TABLE 109     ROW INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN)
      • TABLE 110     ROW BACTERIAL INFECTION MARKET REVENUE, BY APPLICATION TYPE, (2019-2027) ($MN)
      • TABLE 111     ROW VIRAL INFECTION MARKET REVENUE, BY APPLICATION TYPE, (2019-2027) ($MN)
      • TABLE 112     ROW FUNGAL INFECTION MARKET REVENUE, BY APPLICATION TYPE, (2019-2027) ($MN)
      • TABLE 113     ROW OTHER INFECTION MARKET REVENUE, BY APPLICATION TYPE, (2019-2027) ($MN)
      • TABLE 114     ROW INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY END-USER, (2019-2027) ($MN)
      • TABLE 115     ROW INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY MODE OF TEST, (2019-2027) ($MN)
      • TABLE 116     ROW INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY COUNTRY, (2019-2027) ($MN)
      • TABLE 117     PRODUCT LAUNCH (2018-2020)
      • TABLE 118     NEW PRODUCT LAUNCH (2018-2020)
      • TABLE 119     OTHERS (2018-2020)
      • TABLE 120     ABBOTT LABORATORIES: TOTAL REVENUE AND R&D EXPENSES, (2018-2020) ($MN)
      • TABLE 121     ABBOTT LABORATORIES: TOTAL REVENUE, BY SEGMENT, (2018-2020) ($MN)
      • TABLE 122     ABBOTT LABORATORIES: TOTAL REVENUE, BY DIAGNOSTICS SUB-SEGMENT, (2018-2020) ($MN)
      • TABLE 123     ABBOTT LABORATORIES: TOTAL REVENUE, BY GEOGRAPHY, (2018-2020) ($MN)
      • TABLE 124     BECTON, DICKINSON AND COMPANY: TOTAL REVENUE AND R&D EXPENSES, (2018-2020) ($MN)
      • TABLE 125     BECTON, DICKINSON AND COMPANY: TOTAL REVENUE, BY SEGMENT, (2019-2020) ($MN)
      • TABLE 126     BECTON, DICKINSON AND COMPANY: TOTAL REVENUE, BY LIFESCIENCES SUB-SEGMENT, (2018-2020) ($MN)
      • TABLE 127     BECTON, DICKINSON AND COMPANY: TOTAL REVENUE, BY GEOGRAPHY, (2018-2020) ($MN)
      • TABLE 128     BIOMERIEUX SA: TOTAL REVENUE AND R&D EXPENSES, (2018-2020) ($MN)
      • TABLE 129     BIOMERIEUX SA: TOTAL REVENUE, BY SEGMENT, (2018-2020) ($MN)
      • TABLE 130     BIOMERIEUX SA:TOTAL REVENUE, BY GEOGRAPHY, (2018-2020) ($MN)
      • TABLE 131     BIO-RAD LABORATORIES, INC.: TOTAL REVENUE AND R&D EXPENSES, (2018-2020) ($MN)
      • TABLE 132     BIO-RAD LABORATORIES: TOTAL REVENUE, BY SEGMENT, (2018-2020) ($MN)
      • TABLE 133     BIO-RAD LABORATORIES: TOTAL REVENUE, BY GEOGRAPHY, (2018-2020) ($MN)
      • TABLE 134     DANAHER CORPORATION: TOTAL REVENUE AND R&D EXPENSES, (2018-2020) ($MN)
      • TABLE 135     DANAHER CORPORATION: TOTAL REVENUE, BY SEGMENT, (2018-2020) ($MN)
      • TABLE 136     DANAHER CORPORATION: TOTAL REVENUE, BY GEOGRAPHY, (2018-2020) ($MN)
      • TABLE 137     F. HOFFMANN-LA ROCHE LTD: TOTAL REVENUE AND R&D EXPENSES, (2018-2020) ($MN)
      • TABLE 138     F. HOFFMANN-LA ROCHE LTD: TOTAL REVENUE, BY SEGMENT, (2018-2020) ($MN)
      • TABLE 139     F. HOFFMANN-LA ROCHE LTD: TOTAL REVENUE, BY GEOGRAPHY, (2018-2020) ($MN)
      • TABLE 140     HOLOGIC, INC.: TOTAL REVENUE AND R&D EXPENSES, (2018-2020) ($MN)
      • TABLE 141     HOLOGIC, INC.: TOTAL REVENUE, BY SEGMENT, (2018-2020) ($MN)
      • TABLE 142     HOLOGIC, INC.: DIAGNOSIS REVENUE, BY SUB-SEGMENT, (2018-2020) ($MN)
      • TABLE 143     HOLOGIC, INC.: TOTAL REVENUE, BY GEOGRAPHY, (2018-2020) ($MN)
      • TABLE 144     QIAGEN N.V.: TOTAL REVENUE AND R&D EXPENSES, (2018-2020) ($MN)
      • TABLE 145     QIAGEN N.V.: TOTAL REVENUE, BY SEGMENT, (2018-2020) ($MN)
      • TABLE 146     QIAGEN N.V.: TOTAL REVENUE, BY GEOGRAPHY, (2018-2020) ($MN)
      • TABLE 147     SIEMENS HEALTHINEERS GMBH: TOTAL REVENUE AND R&D EXPENSES, (2018-2020) ($MN)
      • TABLE 148     SIEMENS HEALTHINEERS GMBH: TOTAL REVENUE, BY SEGMENT, (2018-2020) ($MN)
      • TABLE 149     SIEMENS HEALTHINEERS GMBH.: TOTAL REVENUE, BY GEOGRAPHY, (2018-2020) ($MN)
      • TABLE 150     THERMO FISHER SCIENTIFIC INC.: TOTAL REVENUE AND R&D EXPENSES, (2018-2020) ($MN)
      • TABLE 151     THERMO FISHER SCIENTIFIC, INC.: TOTAL REVENUE, BY SEGMENT, (2018-2020) ($MN)
      • TABLE 152     THERMO FISHER SCIENTIFIC INC.: TOTAL REVENUE, BY GEOGRAPHY, (2018-2020) ($MN)

      LIST OF FIGURES

      • FIGURE 1     INFECTIOUS DISEASE DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION (2019-2027) ($MN)
      • FIGURE 2     RESEARCH METHODOLOGY: INFECTIOUS DISEASE DIAGNOSTICS GLOBAL MARKET
      • FIGURE 3     INFECTIOUS DISEASE DIAGNOSTICS GLOBAL MARKET: TOP-DOWN AND BOTTOM-UP APPROACH
      • FIGURE 4     INFECTIOUS DISEASE DIAGNOSTICS GLOBAL MARKET: FORECASTING MODEL
      • FIGURE 5     INFECTIOUS DISEASE DIAGNOSTICS GLOBAL MARKET: MARKET BREAKDOWN AND DATA TRIANGULATION
      • FIGURE 6     INFECTIOUS DISEASE DIAGNOSTICS GLOBAL MARKET SEGMENTATION
      • FIGURE 7     INFECTIOUS DISEASE DIAGNOSTICS GLOBAL MARKET SEGMENTATION BY APPLICATION AND REGION
      • FIGURE 8     MARKET DYNAMICS
      • FIGURE 9     INFECTIOUS DISEASE DIAGNOSTICS GLOBAL MARKET: PORTER’S ANALYSIS
      • FIGURE 10     INFECTIOUS DISEASE DIAGNOSTICS: SUPPLY CHAIN ANALYSIS
      • FIGURE 11     INFECTIOUS DISEASE DIAGNOSTICS GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2020 (%)
      • FIGURE 12     MOLECULAR DIAGNOSTICS GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2020 (%)
      • FIGURE 13     IMMUNO DIAGNOSTICS GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2020 (%)
      • FIGURE 14     POINT OF CARE DIAGNOSTICS GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2020 (%)
      • FIGURE 15     CORONAVIRUS DIAGNOSTICS TEST KITS GLOBAL MARKET SHARE, BY REGION, (2020 V/S 2027) (%)
      • FIGURE 16     INFECTIOUS DISEASE DIAGNOSTICS GLOBAL MARKET SHARE, BY PRODUCT (2020 V/S 2027) (%)
      • FIGURE 17     CONSUMABLES GLOBAL MARKET SHARE, BY REGION (2020 V/S 2027) (%)
      • FIGURE 18     INFECTIOUS DISEASE DIAGNOSTICS GLOBAL MARKET SHARE, BY TECHNOLOGY (2020 V/S 2027) (%)
      • FIGURE 19     IDD MOLECULAR DIAGNOSTICS GLOBAL MARKET SHARE, BY TECHNOLOGY TYPE (2020 V/S 2027) (%)
      • FIGURE 20     IDD MOLECULAR DIAGNOSTICS GLOBAL MARKET SHARE, BY REGION (2020 V/S 2027) (%)
      • FIGURE 21     INAAT GLOBAL MARKET SHARE, BY REGION (2020 V/S 2027) (%)
      • FIGURE 22     MICROARRAY GLOBAL MARKET SHARE, BY REGION (2020 V/S 2027) (%)
      • FIGURE 23     ISH GLOBAL MARKET SHARE, BY REGION (2020 V/S 2027) (%)
      • FIGURE 24     IDD IMMUNO DIAGNOSTICS GLOBAL MARKET SHARE, BY TECHNOLOGY TYPE (2020 V/S 2027) (%)
      • FIGURE 25     IDD IMMUNO DIAGNOSTICS GLOBAL MARKET SHARE, BY REGION (2020 V/S 2027) (%)
      • FIGURE 26     INFECTIOUS DISEASE DIAGNOSTICS GLOBAL MARKET SHARE, BY APPLICATION (2020 V/S 2027) (%)
      • FIGURE 27     BACTERIAL INFECTION GLOBAL MARKET SHARE, BY APPLICATION (2020) (%), CAGR (%)
      • FIGURE 28     TREPONEMA PALLIDUM GLOBAL MARKET SHARE, BY REGION (2020 V/S 2027) (%)
      • FIGURE 29     STAPHYLOCOCCUS AUREUS GLOBAL MARKET SHARE, BY REGION (2020 V/S 2027) (%)
      • FIGURE 30     CLOSTRIDIUM DIFFICILE GLOBAL MARKET SHARE, BY REGION (2020 V/S 2027) (%)
      • FIGURE 31     STREPTOCOCCUS (A & B) GLOBAL MARKET SHARE, BY REGION (2020 V/S 2027) (%)
      • FIGURE 32     MRSA GLOBAL MARKET SHARE, BY REGION (2020 V/S 2027) (%)
      • FIGURE 33     CT AND NG GLOBAL MARKET SHARE, BY REGION (2020 V/S 2027) (%)
      • FIGURE 34     OTHER BACTERIAL INFECTION GLOBAL MARKET SHARE, BY REGION (2020 V/S 2027) (%)
      • FIGURE 35     VIRAL INFECTION GLOBAL MARKET SHARE, BY APPLICATION (2020 V/S 2027) (%)
      • FIGURE 36     VIRAL INFECTION GLOBAL MARKET SHARE, BY REGION (2020 V/S 2027) (%)
      • FIGURE 37     FUNGAL INFECTION GLOBAL MARKET SHARE, BY APPLICATION TYPE (2020) (%), CAGR (%)
      • FIGURE 38     OTHER INFECTION GLOBAL MARKET SHARE, BY APPLICATION TYPE (2020) (%), CAGR (%)
      • FIGURE 39     INFECTIOUS DISEASE DIAGNOSTICS GLOBAL MARKET SHARE, BY END-USER (2020 V/S 2027) (%)
      • FIGURE 40     HOSPITAL, ASCS & CLINICS GLOBAL MARKET SHARE, BY REGION (2020 V/S 2027) (%)
      • FIGURE 41     CENTRALIZED LABORATORIES AND CLINICAL TRIALS GLOBAL MARKET SHARE, BY REGION (2020 V/S 2027) (%)
      • FIGURE 42     OTHER END-USERS GLOBAL MARKET SHARE, BY REGION (2020 V/S 2027) (%)
      • FIGURE 43     INFECTIOUS DISEASE DIAGNOSTICS GLOBAL MARKET SHARE, BY MODE OF TESTING (2020 V/S 2027) (%)
      • FIGURE 44     INFECTIOUS DISEASE DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION (2019-2027) ($MN), CAGR (%)
      • FIGURE 45     INFECTIOUS DISEASE DIAGNOSTICS GLOBAL MARKET SHARE BY REGION AND MARKET REVENUE BY COUNTRY, (2020) (%) ($MN)
      • FIGURE 46     NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTICS MARKET SHARE, BY PRODUCT, TECHNOLOGY AND MOLECULAR & IMMUNO DIAGNOSTICS BY TECHNOLOGY TYPE (2020 V/S 2027) (%)
      • FIGURE 47     NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTICS MARKET SHARE, BY APPLICATION (2020 V/S 2027) (%)
      • FIGURE 48     NORTH AMERICA BACTERIAL INFECTION MARKET SHARE, BY APPLICATION TYPE (2020 V/S 2027) (%)
      • FIGURE 49     NORTH AMERICA VIRAL INFECTION MARKET SHARE, BY APPLICATION TYPE (2020 V/S 2027) (%)
      • FIGURE 50     NORTH AMERICA FUNGAL AND OTHER INFECTION MARKET SHARE, BY APPLICATION TYPE (2020 V/S 2027) (%)
      • FIGURE 51     NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTICS MARKET SHARE, BY END-USER AND MODE OF TEST (2020 V/S 2027) (%)
      • FIGURE 52     NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTICS MARKET SHARE, BY COUNTRY (2020 V/S 2027) (%)
      • FIGURE 53     U.S. INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY PRODUCT, TECHNOLOGY, APPLICATION AND END-USER (2020 V/S 2027) ($MN)
      • FIGURE 54     REST OF NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY PRODUCT, TECHNOLOGY, APPLICATION AND END-USER (2020 V/S 2027) ($MN)
      • FIGURE 55     EUROPE INFECTIOUS DISEASE DIAGNOSTICS MARKET SHARE, BY PRODUCT, TECHNOLOGY AND MOLECULAR & IMMUNO DIAGNOSTICS BY TECHNOLOGY TYPE (2020 V/S 2027) (%)
      • FIGURE 56     EUROPE INFECTIOUS DISEASE DIAGNOSTICS MARKET SHARE, BY APPLICATION (2020 V/S 2027) (%)
      • FIGURE 57     EUROPE BACTERIAL INFECTION MARKET SHARE, BY APPLICATION TYPE (2020 V/S 2027) (%)
      • FIGURE 58     EUROPE VIRAL INFECTION MARKET SHARE, BY APPLICATION TYPE (2020 V/S 2027) (%)
      • FIGURE 59     EUROPE FUNGAL AND OTHER INFECTION MARKET SHARE, BY APPLICATION TYPE (2020 V/S 2027) (%)
      • FIGURE 60     EUROPE INFECTIOUS DISEASE DIAGNOSTICS MARKET SHARE, BY END-USER AND MODE OF TEST (2020 V/S 2027) (%)
      • FIGURE 61     EUROPE INFECTIOUS DISEASE DIAGNOSTICS MARKET SHARE, BY COUNTRY (2020 V/S 2027) (%)
      • FIGURE 62     GERMANY INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY PRODUCT, TECHNOLOGY, APPLICATION AND END-USER (2020 V/S 2027) ($MN)
      • FIGURE 63     FRANCE INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY PRODUCT, TECHNOLOGY, APPLICATION AND END-USER (2020 V/S 2027) ($MN)
      • FIGURE 64     ITALY INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY PRODUCT, TECHNOLOGY, APPLICATION AND END-USER (2020 V/S 2027) ($MN)
      • FIGURE 65     REST OF EUROPE INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY PRODUCT, TECHNOLOGY, APPLICATION AND END-USER (2020 V/S 2027) ($MN)
      • FIGURE 66     APAC INFECTIOUS DISEASE DIAGNOSTICS MARKET SHARE, BY PRODUCT, TECHNOLOGY AND MOLECULAR & IMMUNO DIAGNOSTICS BY TECHNOLOGY TYPE (2020 V/S 2027) (%)
      • FIGURE 67     APAC INFECTIOUS DISEASE DIAGNOSTICS MARKET SHARE, BY APPLICATION (2020 V/S 2027) (%)
      • FIGURE 68     APAC BACTERIAL INFECTION MARKET SHARE, BY APPLICATION TYPE (2020 V/S 2027) (%)
      • FIGURE 69     APAC VIRAL INFECTION MARKET SHARE, BY APPLICATION TYPE (2020 V/S 2027) (%)
      • FIGURE 70     APAC FUNGAL AND OTHER INFECTION MARKET SHARE, BY APPLICATION TYPE (2020 V/S 2027) (%)
      • FIGURE 71     APAC INFECTIOUS DISEASE DIAGNOSTICS MARKET SHARE, BY END-USER AND MODE OF TEST (2020 V/S 2027) (%)
      • FIGURE 72     APAC INFECTIOUS DISEASE DIAGNOSTICS MARKET SHARE, BY COUNTRY (2020 V/S 2027) (%)
      • FIGURE 73     JAPAN INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY PRODUCT, TECHNOLOGY, APPLICATION AND END-USER (2020 V/S 2027) ($MN)
      • FIGURE 74     CHINA INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY PRODUCT, TECHNOLOGY, APPLICATION AND END-USER (2020 V/S 2027) ($MN)
      • FIGURE 75     INDIA INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY PRODUCT, TECHNOLOGY, APPLICATION AND END-USER (2020 V/S 2027) ($MN)
      • FIGURE 76     REST OF APAC INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY PRODUCT, TECHNOLOGY, APPLICATION AND END-USER (2020 V/S 2027) ($MN)
      • FIGURE 77     ROW INFECTIOUS DISEASE DIAGNOSTICS MARKET SHARE, BY PRODUCT, TECHNOLOGY AND MOLECULAR & IMMUNO DIAGNOSTICS BY TECHNOLOGY TYPE (2020 V/S 2027) (%)
      • FIGURE 78     ROW INFECTIOUS DISEASE DIAGNOSTICS MARKET SHARE, BY APPLICATION (2020 V/S 2027) (%)
      • FIGURE 79     ROW BACTERIAL INFECTION MARKET SHARE, BY APPLICATION TYPE (2020 V/S 2027) (%)
      • FIGURE 80     ROW VIRAL INFECTION MARKET SHARE, BY APPLICATION TYPE (2020 V/S 2027) (%)
      • FIGURE 81     ROW FUNGAL AND OTHER INFECTION MARKET SHARE, BY APPLICATION TYPE (2020 V/S 2027) (%)
      • FIGURE 82     ROW INFECTIOUS DISEASE DIAGNOSTICS MARKET SHARE, BY END-USER AND MODE OF TEST (2020 V/S 2027) (%)
      • FIGURE 83     ROW INFECTIOUS DISEASE DIAGNOSTICS MARKET SHARE, BY COUNTRY (2020 V/S 2027) (%)
      • FIGURE 84     BRAZIL INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY PRODUCT, TECHNOLOGY, APPLICATION AND END-USER (2020 V/S 2027) ($MN)
      • FIGURE 85     REST OF LATAM INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY PRODUCT, TECHNOLOGY, APPLICATION AND END-USER (2020 V/S 2027) ($MN)
      • FIGURE 86     MIDDLE EAST & AFRICA INFECTIOUS DISEASE DIAGNOSTICS MARKET REVENUE, BY PRODUCT, TECHNOLOGY, APPLICATION AND END-USER (2020 V/S 2027) ($MN)
      • FIGURE 87     KEY GROWTH STRATEGIES, (2018-2020)
      • FIGURE 88     SWOT: ABBOTT LABORATORIES
      • FIGURE 89     SWOT: BECTON, DICKINSON AND COMPANY
      • FIGURE 90     SWOT: BIOMERIEUX SA
      • FIGURE 91     SWOT: BIO-RAD LABORATORIES, INC.
      • FIGURE 92     SWOT: DANAHER CORPORATION
      • FIGURE 93     SWOT: F.HOFFMANN-LA ROCHE LTD.
      • FIGURE 94     SWOT: HOLOGIC, INC.
      • FIGURE 95     SWOT: QIAGEN N.V
      • FIGURE 96     SWOT: SIEMENS HEALTHINEERS GMBH
      • FIGURE 97     SWOT: THERMO FISHER SCIENTIFIC INC.

      LIST OF COMPANIES MENTIONED IN THE REPORT

      • 1     1Drop Diagnostics
      • 2     Abbott Laboratories
      • 3     Access Bio Inc
      • 4     AdvaCare Pharma
      • 5     Agilent Technologies
      • 6     Altona Diagnostics GmbH
      • 7     Applied DNA Sciences, Inc.
      • 8     Ashdod
      • 9     Atila BioSystems, Inc.
      • 10     AusDiagnostics Pty. Ltd.
      • 11     Autobio Diagnostics Co. Ltd.
      • 12     Avellino Lab USA, Inc.
      • 13     Becton, Dickinson and Company
      • 14     BGI Genomics Co. Ltd
      • 15     BioFire Defense, LLC
      • 16     BioMerieux SA
      • 17     Biopromic AB
      • 18     Bio-Rad Laboratories, Inc.
      • 19     BIORON Diagnostics GmbH
      • 20     BMT Diagnostics
      • 21     Cellex Inc.
      • 22     CerTest BIOTEC SL
      • 23     Chembio Diagnostic System, Inc
      • 24     Co-diagnostics, inc.
      • 25     Coris Bioconcept SPRL
      • 26     Cosara Clinical Laboratories
      • 27     Creative Diagnostics
      • 28     CTK Biotech, Inc
      • 29     Danaher Corporation
      • 30     Day Zero Diagnostics Inc.
      • 31     DiaCarta, Inc.
      • 32     Diasorin S.p.A
      • 33     ELITechGroup
      • 34     EUROIMMUN US Inc.
      • 35     Eurospital
      • 36     F. Hoffmann-La Roche
      • 37     Fosun Pharma USA Inc.
      • 38     Fujirebio Diagnostics, Inc.
      • 39     Fusion Genomics Corporation
      • 40     Genefron Ltd
      • 41     GenMark Diagnostics, Inc.
      • 42     GenoSensor, LLC
      • 43     GenPath
      • 44     GNA Biosolutions GmbH
      • 45     Gnomegen LLC
      • 46     Hain Lifescience GmbH
      • 47     Hibergene Diagnostics Limited
      • 48     Hologic, Inc.
      • 49     InBios International, Inc.
      • 50     Incas Diagnostics
      • 51     Innovatek Medical Inc.
      • 52     Ipsum Diagnostics, LLC
      • 53     IVD Research, Inc.
      • 54     Karius, Inc.
      • 55     LabGenomics Co., Ltd.
      • 56     Launch Diagnostics Limited
      • 57     Luminex Corporation
      • 58     Lytech Co. Ltd
      • 59     Median Diagnostics
      • 60     Memed Diagnostics
      • 61     Merck KGaA
      • 62     Mesa Biotech Inc.
      • 63     Miravista Diagnostics
      • 64     MP Biomedicals
      • 65     Mycodart Inc.
      • 66     NeuMoDx Molecular, Inc.
      • 67     Novamed Ltd
      • 68     Novartis International AG
      • 69     Omega Diagnostics
      • 70     OPTI Medical Systems, Inc.
      • 71     Ortho-Clinical Diagnostics, Inc.
      • 72     OSANG Healthcare
      • 73     Otsuka Pharmaceutical Co., Ltd
      • 74     Oxford biosystems
      • 75     PEPperPRINT
      • 76     PerkinElmer, Inc.
      • 77     Primerdesign Ltd.
      • 78     Promega Corporation
      • 79     Qiagen N.V.
      • 80     QuanDx
      • 81     QuantuMDx Group Ltd.
      • 82     Quest Diagnostics
      • 83     Quidel Corporation
      • 84     Quotient Diagnostics Ltd
      • 85     Randox Laboratories Ltd
      • 86     R-Biopharm AG
      • 87     Rheonix, Inc.
      • 88     RPC Diagnostics
      • 89     Sanbio B.V
      • 90     Sansure BioTech Inc.
      • 91     Savyon Diagnostics
      • 92     ScienCell Research Laboratories
      • 93     SEASUN BIOMATERIALS
      • 94     Seegene, Inc.
      • 95     Sekisui Diagnostics
      • 96     Serion Diagnostics
      • 97     Sherlock BioSciences, Inc.
      • 98     Siemens Healthineers GmbH
      • 99     Sigma Diagnostics Inc.
      • 100     SpeeDx Pty, Ltd
      • 101     T2 Biosystems, Inc.
      • 102     Thermo Fisher Scientific
      • 103     ThromboDx BV
      • 104     Trax Management Services Inc.
      • 105     Tulip Diagnostics (P) Ltd
      • 106     VirionSerion GmbH
      • 107     Wantai Biological Pharmacy Enterprise Co., Ltd.
      • 108     ZeptoMetrix Corporation
      • 109     Zymo Research Corporation